Literature DB >> 7068190

Urinary prostaglandins in the Lyon strains of hypertensive, normotensive, and low blood pressure rats.

D Benzoni, M Vincent, J Sassard.   

Abstract

A longitudinal study of the urinary excretion of prostaglandins (PGs) E and F alpha was performed in simultaneously selected hypertensive (LH), normotensive (LN), and low blood pressure (LL) female rats of the Lyon strains aged from 5 to 45 weeks. The urinary excretion of PGE did not significantly differ between LL and LN rats whereas in LH rats it was found to be significantly lower than that of LN or LL rats starting at the age of 32 weeks. The urinary excretion of PGF alpha was significantly reduced in both LL and LH rats; however, this decrease was more marked in LH than in LL animals and, from 9 weeks of age, the urinary PGF alpha were significantly lower in LH than in age-matched LL rats. In addition, both PGE and PGF alpha were found to be significantly and negatively related to the systolic blood pressure level in LH rate (r = -0.56, n = 58, p less than 0.001 for PGE; and r = -0.78, n = 58, p less than 0.001 for PGF alpha) but not in LN of LL animals. In conclusion, it seems unlikely that renal PGs could play a primary role in the spontaneous hypertension observed in the Lyon strain of rats.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7068190     DOI: 10.1161/01.hyp.4.2.325

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  2 in total

1.  Effect of a five-week swimming program on rat bone: a histomorphometric study.

Authors:  S Bourrin; F Ghaemmaghami; L Vico; D Chappard; C Gharib; C Alexandre
Journal:  Calcif Tissue Int       Date:  1992-08       Impact factor: 4.333

2.  Contribution of independent and pleiotropic genetic effects in the metabolic syndrome in a hypertensive rat.

Authors:  Man Chun John Ma; Janette M Pettus; Jessica A Jakoubek; Matthew G Traxler; Karen C Clark; Amanda K Mennie; Anne E Kwitek
Journal:  PLoS One       Date:  2017-08-08       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.